Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
April 14, 2024 Markets Rattle: Iran-Israel Conflict and Economic Data Ahead
Apple’s Technical Climb To $240 By Year-End
April 15, 2024
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
ALNY Stock News and Mentions of Alnylam Pharmaceuticals, Inc. Stocktwits
Updated: April 20, 2024 (09:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Alnylam Pharmaceuticals Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Alnylam Pharmaceuticals, Inc. (ALNY).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Alnylam Pharmaceuticals stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Alnylam Pharmaceuticals, Inc. (ALNY)
April 19, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Alnylam Pharmaceuticals? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals's ALNY short percent of float has fallen 9.57% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 2.55% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 13, 2024 (06:22) / "Stocknews.com" (by Defense World Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Upgraded at StockNews.com
Alnylam Pharmaceuticals ( NASDAQ:ALNY - Get Free Report ) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Saturday. Several other equities analysts also recently weighed in on the company.
In Article Trend: Somewhat-Bullish
April 11, 2024 (11:05) / "Benzinga" (by Globe Newswire)
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board - Codexis ( NASDAQ:CDXS )
REDWOOD CITY, Calif., April 11, 2024 ( GLOBE NEWSWIRE ) -- Codexis, Inc. CDXS, a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board ( SAB ) .
In Article Trend: Neutral
April 11, 2024 (11:05) / "GlobeNewswire" (by Inc.)
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform ...
In Article Trend: Neutral
April 8, 2024 (18:37) / "Benzinga" (by Vandana Singh)
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
On Sunday, Alnylam Pharmaceuticals Inc. ALNY presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard-of-care antihypertensives.
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:44) / "Zacks Commentary" (by Zacks Equity Research)
Why Alnylam Pharmaceuticals ( ALNY ) Stock Might be a Great Pick
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
In Article Trend: Bullish
April 7, 2024 (05:58) / "Stocknews.com" (by Defense World Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Cut to Hold at StockNews.com
Alnylam Pharmaceuticals ( NASDAQ:ALNY - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Friday. ALNY has been the subject of a number of other research reports.
In Article Trend: Somewhat-Bullish
April 6, 2024 (20:16) / "GlobeNewswire" (by Novartis Pharma AG)
New Novartis data show early addition of twice-yearly* Leqvio® ( inclisiran ) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Basel, April 6, 2024 - Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio® ( inclisiran ) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol ( ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (19:00) / "Benzinga" (by Benzinga Insights)
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 1.97% on an annualized basis producing an average annual return of 15.0%. Currently, Alnylam Pharmaceuticals has a market capitalization of $19.33 billion.
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Autolus Therapeutics Announces Changes to its Board of Directors - Autolus Therapeutics ( NASDAQ:AUTL )
LONDON, April 01, 2024 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director.
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:00) / "GlobeNewswire" (by Autolus Inc.)
Autolus Therapeutics Announces Changes to its Board of Directors
LONDON, April 01, 2024 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc ( Nasdaq: AUTL ) , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive ...
In Article Trend: Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 23, 2024 (09:10) / "Stocknews.com" (by Defense World Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Upgraded to "Buy" at StockNews.com
StockNews.com upgraded shares of Alnylam Pharmaceuticals ( NASDAQ:ALNY - Free Report ) from a hold rating to a buy rating in a report published on Friday morning.
In Article Trend: Somewhat-Bullish
March 22, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should Invesco NASDAQ Next Gen 100 ETF ( QQQJ ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 1.77% on an annualized basis producing an average annual return of 14.93%. Currently, Alnylam Pharmaceuticals has a market capitalization of $18.95 billion.
In Article Trend: Somewhat-Bullish
March 15, 2024 (11:02) / "Stocknews.com" (by ABMN Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Stock Rating Lowered by StockNews.com
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Stock Rating Lowered by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (11:00) / "Stocknews.com" (by Defense World Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Downgraded by StockNews.com to Hold
StockNews.com cut shares of Alnylam Pharmaceuticals ( NASDAQ:ALNY - Free Report ) from a buy rating to a hold rating in a research note issued to investors on Thursday morning.
In Article Trend: Somewhat-Bullish
March 6, 2024 (16:26) / "Zacks Commentary" (by Zacks Equity Research)
Alnylam ( ALNY ) , Roche's Blood Pressure Drug Meets Study Goal
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
In Article Trend: Somewhat-Bullish
March 5, 2024 (19:38) / "Benzinga" (by Vandana Singh)
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Tuesday, Alnylam Pharmaceuticals Inc ALNY said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen ( AGT ) for hypertension, met the primary endpoint.
In Article Trend: Somewhat-Bullish
March 3, 2024 (15:15) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals ... PR ...
In Article Trend: Neutral
February 28, 2024 (21:00) / "Benzinga" (by Benzinga Insights)
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 2.37% on an annualized basis producing an average annual return of 16.59%. Currently, Alnylam Pharmaceuticals has a market capitalization of $19.60 billion.
In Article Trend: Somewhat-Bullish
February 28, 2024 (20:12) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ( "Alnylam" or the "Company" ) ALNY. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
In Article Trend: Neutral
February 23, 2024 (13:30) / "Investors Business Daily" (by ALLISON GATLIN)
There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It
Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...
In Article Trend: Neutral
February 21, 2024 (07:18) / "Stocknews.com" (by Defense World Staff)
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Downgraded by StockNews.com to "Buy"
Alnylam Pharmaceuticals ( NASDAQ:ALNY - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Wednesday. Other equities analysts also recently issued research reports about the stock.
In Article Trend: Somewhat-Bullish
February 20, 2024 (13:05) / "Benzinga" (by Globe Newswire)
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board - Codexis ( NASDAQ:CDXS )
REDWOOD CITY, Calif., Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Codexis, Inc. CDXS, a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company's Strategic Advisory Board ( SAB ) , joining John Maraganore, PhD, the founder and former ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website